Work

Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

Year: 2021

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2021.39.15_suppl.11515

Authors: Margaret von Mehren, Sujana Movva, Elizabeth A. Handorf, Priscilla Merriam, Jeffrey A. Morgan, Edwin Choy, Eric Daniel Tetzlaff, Emma Barker, Allisa Cherae Harley, April King, Sahar Matloob, Erika Jerome, Lori Rink, Suzanne George

Institutions: Fox Chase Cancer Center, Dana-Farber Cancer Institute, Massachusetts General Hospital, Harvard University

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Fox Chase Cancer Center

OpenAlex ID: W3170210367

Cites:

Cited by:

Related to: 10